Curex BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Curex Legit? A Baseline Regulatory Assessment

Curex operates as a cash-pay telehealth company, meaning patients pay out of pocket rather than through insurance. The company offers GLP-1 weight-loss treatment, typically via compounded semaglutide, alongside allergy immunotherapy services. Whether a company is "legit" involves at least three separate questions: Is it BBB-accredited? Are its prescribers licensed? Are its products FDA-approved?

Curex is not currently BBB-accredited. The Better Business Bureau uses accreditation as a separate designation from its letter grade, and the absence of accreditation means the company has not agreed to the BBB's standards for trust. Consumers can verify current BBB standing at bbb.org directly, as ratings change over time.

Prescriber Licensing

Telehealth prescribers must hold active state licenses in every state where they write prescriptions. The Federation of State Medical Boards maintains a public physician data center that consumers can search. Patients should confirm their assigned prescriber is licensed in their home state before accepting any prescription.

Product Regulatory Status

Curex's GLP-1 offering uses compounded semaglutide, not Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg, Novo Nordisk) or Wegovy (semaglutide 2.4 mg, Novo Nordisk). The FDA has issued explicit guidance on compounded semaglutide, stating that compounded drugs are not FDA-approved and have not undergone FDA review for safety, efficacy, or manufacturing quality. That is not a minor footnote. It is the starting point for any consumer evaluating a compounded GLP-1 program.

What "Cash-Pay" Means for Consumer Protections

Insurance-covered prescriptions travel through pharmacy benefit managers and state insurance commissioners, creating audit trails. Cash-pay telehealth operates outside that infrastructure. Consumers who experience billing disputes have fewer automatic escalation paths, which may partly explain why billing-related complaints are the most common category seen on consumer review platforms for services like Curex.

FDA Warnings on Compounded Semaglutide: The Regulatory Context

The FDA has taken concrete enforcement steps regarding compounded GLP-1 products. Understanding those steps is necessary before evaluating any specific complaint pattern.

The 503A and 503B Compounding Framework

Under 21 U.S.C. § 503A and § 503B, pharmacies may compound drugs under specific conditions. FDA has clarified that semaglutide was placed on the FDA's drug shortage list, which temporarily opened a pathway for compounding. However, the FDA updated its shortage determination in 2024, and compounding status is subject to change. Platforms that dispensed compounded semaglutide under shortage exemptions may face supply disruptions or compliance requirements as shortage status evolves.

Dosing Error Risks

The FDA's MedWatch safety reporting database has received reports of dosing errors associated with compounded semaglutide, including patients receiving 10-fold overdoses due to concentration differences between compounded formulations and branded products. A branded Wegovy pen delivers a fixed 2.4 mg dose. Compounded vials require patient self-calculation of volume based on the compounding pharmacy's specific concentration, which varies. That calculation step introduces error risk that does not exist with the branded auto-injector.

REMS Considerations

Branded semaglutide does not carry a Risk Evaluation and Mitigation Strategy (REMS), but the FDA's general drug safety framework still applies to prescribers who must evaluate appropriateness. Telehealth prescribers who conduct only asynchronous assessments (questionnaire-based, no live video) may not meet the standard of care for GLP-1 prescribing outlined in the Endocrine Society's 2023 obesity pharmacotherapy guidelines, which recommend a thorough history including personal or family history of medullary thyroid carcinoma before prescribing any GLP-1 receptor agonist. The Endocrine Society clinical practice guideline is publicly available and outlines that evaluation standard.

Curex BBB Complaint Patterns

Consumer complaints filed through the Better Business Bureau provide a structured signal about where a company's operations break down. Patterns across multiple complaints are more informative than individual one-star reviews.

Billing and Subscription Disputes

The most frequently recurring complaint category for Curex on the BBB involves billing. Specific complaint themes include: charges continuing after cancellation requests, difficulty reaching customer service to process refunds, and subscription terms that were not clearly disclosed at enrollment. These are administrative and contractual failures, distinct from clinical safety complaints.

The FTC's negative option rule governs subscription cancellations and requires clear disclosure of cancellation terms. Consumers who believe a company violated these terms may file a complaint with the FTC at reportfraud.ftc.gov.

Fulfillment Delays

A second complaint cluster involves medication delays. Patients who enrolled expecting weekly GLP-1 injections reported multi-week gaps between payment and delivery. Fulfillment delays with compounded semaglutide reflect supply chain complexity: the prescribing platform, the compounding pharmacy (a separate entity), and the shipping carrier each represent a potential delay point. Consumers should ask any telehealth platform to identify the specific 503A or 503B pharmacy dispensing their medication before enrolling.

Clinical Interaction Complaints

A smaller but clinically significant complaint category involves difficulty accessing a prescriber after side effects emerged. GLP-1 receptor agonists carry a class-wide risk of nausea, vomiting, and gastroparesis. The FDA's approved labeling for semaglutide includes warnings for acute pancreatitis, gallbladder disease, and acute kidney injury secondary to dehydration. Patients who cannot reach a clinician during an adverse event are at elevated risk. Any telehealth platform offering GLP-1 prescriptions should provide a documented clinical escalation pathway, including a phone number that reaches a licensed clinician within 24 hours.

GLP-1 Efficacy Data: The Baseline Against Which Curex Should Be Judged

Telehealth platforms that offer GLP-1 medications are only as useful as the underlying drug's evidence base. That evidence is strong for the branded, FDA-approved versions.

STEP-1 Trial Data

In STEP-1 (N=1,961), semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (P<0.001). Wilding et al., NEJM 2021 reported that 86.4% of participants in the semaglutide group achieved at least 5% weight loss. Those results apply specifically to the branded, FDA-approved 2.4 mg subcutaneous formulation. Whether compounded semaglutide at the same nominal dose produces identical pharmacokinetics has not been established in a published randomized controlled trial.

STEP-4 Maintenance Data

STEP-4 (N=803) examined what happens when patients stop semaglutide after 20 weeks of treatment. Rubino et al., JAMA 2021 found participants who switched to placebo regained two-thirds of their prior weight loss within 48 weeks of discontinuation. This finding is clinically relevant for Curex patients who enroll expecting a short-term fix. GLP-1 therapy requires indefinite use or transition to a behavioral maintenance program to preserve weight loss.

SELECT Cardiovascular Trial

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, with no history of diabetes. Lincoff et al., NEJM 2023 reported a hazard ratio of 0.80 (95% CI 0.72 to 0.90). Again, these results are from the branded Wegovy formulation, not compounded alternatives.

How Curex Compares to Regulatory Best Practices for Telehealth GLP-1 Prescribing

The American Telemedicine Association and individual state medical boards have published standards for telehealth prescribing. The core requirements most relevant to GLP-1 platforms are: establishing a valid prescriber-patient relationship, conducting an adequate medical history, and providing ongoing clinical monitoring.

Prescriber-Patient Relationship Requirements

Most states require at minimum a synchronous audio-video evaluation before a controlled substance or high-risk medication can be prescribed. GLP-1 receptor agonists are not controlled substances under federal scheduling, but several states have begun applying similar standards to weight-loss medications given their misuse potential. The DEA telemedicine prescribing rules and follow-on guidance from 2023 are the relevant federal framework, even though semaglutide itself is not scheduled.

Contraindication Screening

The FDA-approved labeling for semaglutide, accessible via FDA's drug database, lists personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 as contraindications. Asynchronous questionnaire-based intake processes must capture this history accurately. Platforms that allow patients to self-report without clinical verification introduce contraindication screening gaps.

Lab Monitoring

The Endocrine Society's obesity pharmacotherapy guidance recommends baseline and follow-up metabolic panels, thyroid function assessment where indicated, and HbA1c measurement in patients at risk for type 2 diabetes. Telehealth platforms that prescribe GLP-1 medications without requiring baseline labs fall below the standard of care described in published guidelines from endocrine.org.

HealthRX Telehealth GLP-1 Platform Evaluation Framework

Before enrolling in any cash-pay GLP-1 program, patients should confirm answers to these five questions:

1. Is the medication FDA-approved (Wegovy, Ozempic, Zepbound) or compounded? If compounded, which 503A or 503B pharmacy dispenses it?
2. Does the intake process include a synchronous (live video or phone) clinical evaluation, or is it questionnaire-only?
3. Are baseline labs (metabolic panel, HbA1c, lipids) required before the first prescription?
4. What is the documented escalation pathway if a serious adverse event occurs after hours?
5. What are the exact cancellation and refund terms, and are they disclosed before payment?

No single "yes" answer makes a platform safe. All five matter.

State Medical Board and LegitScript Verification

Two verification steps are available to any consumer and take under five minutes each.

State Medical Board Lookup

Every licensed physician, nurse practitioner, and physician assistant has a publicly searchable license record. The Federation of State Medical Boards aggregates links to individual state board lookup tools. Patients should search their assigned Curex prescriber by name before accepting a prescription. An expired or disciplined license is disqualifying, and the search is free.

LegitScript Certification

LegitScript is an FDA-recognized third-party certifier of online pharmacies and telehealth platforms. LegitScript certification requires verification of prescriber licensing, pharmacy licensure, prescription requirement compliance, and privacy policy adequacy. Platforms that carry current LegitScript certification have passed an external audit. Consumers should confirm Curex's current LegitScript status directly at legitscript.com, as certifications can be granted, suspended, or revoked.

What Consumers Should Do if They Have a Curex Complaint

Consumers who have already experienced a billing, fulfillment, or clinical problem with Curex have several escalation options.

BBB Complaint Filing

Filing a complaint at bbb.org creates a public record and gives the company an opportunity to respond. BBB complaints are not legally binding but do affect a company's public-facing rating and can surface patterns regulators notice.

FTC Report

The FTC's consumer fraud reporting portal accepts complaints about deceptive subscription practices, unauthorized charges, and misleading advertising. The FTC uses aggregate complaint data to identify enforcement targets. Individual reports contribute to that aggregate even when no individual case is opened.

State Attorney General

State attorneys general have jurisdiction over consumer protection violations within their state. If a patient enrolled in Curex from California, for example, the California AG's consumer protection division accepts complaints about telehealth billing practices. Most state AG offices have online complaint forms.

FDA MedWatch

Adverse drug events, including those associated with compounded semaglutide, should be reported to the FDA's MedWatch program. This applies to dosing errors, unexpected side effects, and product quality problems (e.g., particulate matter in a vial). MedWatch reports are reviewed by the FDA's pharmacovigilance staff and contribute to post-market safety monitoring.

The Broader Compounded Semaglutide Safety Picture

Curex is one of dozens of cash-pay platforms dispensing compounded semaglutide. The complaint trends observed at Curex reflect sector-wide issues, not necessarily company-specific malfeasance. Understanding the broader context helps consumers calibrate risk.

FDA Warning Letters

The FDA has issued warning letters to multiple compounding pharmacies regarding semaglutide. These letters are publicly accessible at FDA's warning letter database. Issues cited include cGMP violations, lack of sterility testing, and mislabeled concentrations. Patients receiving compounded semaglutide from any platform should ask for documentation of the dispensing pharmacy's most recent inspection record.

ISMP Safety Alert

The Institute for Safe Medication Practices published a safety alert in 2023 documenting patient harm from compounded semaglutide dosing errors, including hospitalizations. The ISMP operates the national medication errors reporting program in cooperation with the FDA. Their published alerts are available at ismp.org and represent a direct, documented harm signal separate from consumer review complaints.

Tirzepatide Compounding

Several platforms, including some competitors, have shifted from compounded semaglutide to compounded tirzepatide (the active ingredient in Mounjaro and Zepbound) as regulatory scrutiny on semaglutide increased. The same FDA framework applies: tirzepatide's approved labeling covers the branded Eli Lilly formulations only. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo. Jastreboff et al., NEJM 2022 reported those results for the FDA-approved formulation, not compounded alternatives.

Clinical Summary: Who Should and Should Not Use Cash-Pay GLP-1 Telehealth

Not all cash-pay GLP-1 telehealth is equivalent in quality. Some platforms do conduct synchronous evaluations, require labs, use FDA-approved branded medications, and provide clinical after-hours coverage. Others do not. The complaint trends at Curex and similar platforms correlate with the absence of those safeguards.

Patients who may benefit from cash-pay telehealth GLP-1 programs are those with a BMI of 30 or higher (or 27 or higher with an obesity-related comorbidity, per the FDA's approved indication for Wegovy), no contraindications, and the financial means to sustain long-term treatment (branded Wegovy carries a list price above $1,300 per month without insurance).

Patients who should not proceed without in-person evaluation first include those with a personal or family history of thyroid cancer, active gallbladder disease, a history of pancreatitis, severe gastroparesis, or current pregnancy. The FDA's prescribing information for semaglutide is explicit that these populations are either contraindicated or require careful risk-benefit discussion that a questionnaire cannot adequately capture.

Patients who already have a primary care physician or endocrinologist should discuss GLP-1 therapy with that provider before enrolling in a cash-pay platform. Insurance coverage for branded semaglutide, while inconsistent, does exist for some commercial plans and for Medicare beneficiaries with qualifying diagnoses. The CDC's obesity data and resources page provides population-level context, and the AHA's guidance on cardiovascular risk reduction includes weight management as a modifiable cardiovascular risk factor.

Any patient already using Curex who has experienced a side effect should document it, report it to FDA MedWatch at fda.gov/safety/medwatch, and contact their state medical board if they believe the prescribing standard of care was not met.